DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Genetic Analysis of Non-Human Animal Models to Understand the Genomic Architecture of Substance Use Disorders and Addictive Behaviors (U01 Clinical Trial Not Allowed)

Date: June 10, 2021

Time: 12:00 PM to 4:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Ipolia R. Ramadan, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021
Bethesda, MD 20892
(301) 827-4471
ramadanir@mail.nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Cutting-Edge Basic Research Awards (CEBRA) (R21)

Date: June 11, 2021

Time: 10:00 AM to 5:30 PM

Agenda: To review and evaluate grant applications
Place: National Institutes of Health
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Sheila Pirooznia, Ph.D.
Scientific Review Officer
Division of Extramural Review
Scientific Review Branch
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021
Bethesda, MD 20892
(301) 496-9350
sheila.pirooznia@nih.gov

Name of Committee: National Institute on Drug Abuse Initial Review Group Medication Development Research Study Section

Date: July 21, 2021

Time: 10:00 AM to 5:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Preethy Nayar, Ph.D., M.B.B.S.
Scientific Review Officer
Scientific Review Branch
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021
Bethesda, MD 20892
301-443-4577
nayarp2@csr.nih.gov


Tyeshia M. Roberson,
Program Analyst,
Office of Federal Advisory Committee Policy.